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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.10.001BACKGROUND: This study presents descriptive epidemiological data related to prostate cancer cases diag-
nosed from 2001 to 2008 among Saudi men, including the frequency and percentage of cases, the crude inci-
dence rate (CIR) and the age-standardised incidence rate (ASIR) adjusted by region and year of diagnosis.
METHODS: This is a retrospective descriptive epidemiological analysis of all Saudi prostate cancer cases
recorded in the Saudi Cancer Registry (SCR) between January 2001 and December 2008. Statistical analyses
were conducted using descriptive statistics, the Poisson regression model, a simple linear regression model
and analysis of variance with the Statistical Package for the Social Sciences version 20.0 (SPSS).
RESULTS: A total of 1739 cases were registered in the SCR between January 2001 and December 2008. The
eastern region of Saudi Arabia had the highest overall ASIR at 10.1 per 100,000 men, followed by Riyadh at
7.1 and Makkah at 5.2, while Jizan and Najran had the lowest average ASIRs at 1.4 and at 2.0, respectively.
The Poisson regression model for the region of Jizan shows that the incidence rate ratio (IRR) was significantly
higher (p < 0.001); for the regions of Riyadh at 3.43 times (95% CI, 3.13–3.73), followed by Makkah at 2.56
(95% CI, 2.38–2.74) and the eastern province at 1.93 (95% CI, 1.64–2.23). The annual prediction of the CIR
of prostate cancer in Saudi Arabia could be defined by the equation 1.53 + (0.094 · Years), and the prediction
of the ASIR could be defined by the equation 2.98 + (0.182 · Years).
CONCLUSION: There was a steady increase in the CIRs and ASIRs for prostate cancer between 2001 and 2008.
The eastern region, Riyadh and Makkah had the highest overall ASIR in Saudi Arabia. Further effective screening
programmes and active treatment measures are needed to control prostate cancer disease among Saudi men.Prostate cancer is one of the most common can-cers among men, and it is the sixth leadingcause of cancer-related mortality in men
worldwide.1–4 It has become a signiﬁcant health prob-
lem in both developed and developing countries.2,4
The incidence rate of prostate cancer differs from
country to country, and the proportion of cases vary
by more than 25-fold globally.5 According to the
American Cancer Society, in 2008 an estimated
903,500 new cases of prostate cancer were reported
among men internationally, while the number of
deaths was 258,400.4,5HeProstate cancer is the second leading cause of
death among men in the United States,1 and will
inﬂuence one in six males during their life span. In
2013, it is estimated that 238,590 new cases will be
detected and 29,720 men will die from prostate can-
cer.6 The burden of prostate cancer has increased in
Europe, with an estimated 379,000 new cases and
94,000 deaths reported in 2008.7 In addition, mortal-
ity rates continue to increase in African people, and
decrease in the Asian population.4,7
In Saudi Arabia, the International Agency for Re-
search on Cancer (IARC) estimated that thematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 1. Segi (World) standard: For making comparisons with
intermediate-age population (Segi, 1960). It can be used in direct
method of standardization to calculate the ASIR & ASMR.
Age group Segi (World) standard
0–4 12,000
5–9 10,000
10–14 9000
15–19 9000
20–24 8000
25–29 8000
30–34 6000
35–39 6000
40–44 6000
45–49 6000
50–54 5000
55–59 4000
60–64 4000
65–69 3000
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age-standardised incidence rate (ASIR) for prostate
cancer was 7.7 per 100,000 men in 2008, and the
age-standardised mortality rate (ASMR) was 5.1 per
100,000 men.7 Furthermore, the registry of the King
Faisal Specialist Hospital and Research Centre (2011)
recorded 1213 cases (1.7%) of prostate cancer admit-
ted to the hospital during the years 1975–2011.8 In
2008, the Saudi Cancer Registry (SCR) reported that
prostate cancer ranked sixth in cancer incidence
among Saudi men.9
The age standardized incidence rate of prostate
cancer in Saudi Arabia is very low in comparison to
Arab Gulf and European countries. For example, in
2008, the reported ASIRs for Qatar, Bahrain, Ku-
wait, and United Arab Emirates were higher than
Saudi Arabia at 15, 13.3, 11.6 and 9.6, respectively.7
Despite lacking information about prostate cancer in
Saudi Arabia, except for the SCR reports, we have at-
tempted to study the incidence of prostate cancer in
different regions of Saudi Arabia during the years
2001–2008. The objectives of this study are to inves-
tigate and describe the distribution of prostate cancer
in terms of the characteristics of person, place and
time among Saudi men.1070–74 2000
75+ 2000
Total 100,000MATERIALS AND METHODS
We conducted a retrospective descriptive epidemio-
logical study of all Saudi men prostate cancer cases
diagnosed between January 2001 and December
2008. Data for cancer in Saudi Arabia are publicly
available and easily accessible. The data sources for
this study were made possible by the SCR, a popula-
tion-based registry established in 1994 by the Minis-
try of Health in Saudi Arabia. The data cannot be
obtained directly from the SCR, except through pub-
lished reports. There were no available data from
1994 to 2000, and the latest published report of the
SCR was in 2008. Other cancer reports have been
published by the King Faisal Specialist Hospital and
Research Center, which is a hospital-based registry.
We were therefore unable to use them for a general
analysis of the Saudi male population.
Since its establishment, the SCR has been provid-
ing reports on the pattern of cancer in Saudi Arabia
with a primary objective of deﬁning the population-
based incidence of the disease. Based on these data,
there are currently comprehensive reports for 13
administrative regions from 2001 to 2008 that outline
the frequency and percentage of cases, the CIR and
the ASIR adjusted by the provinces of Saudi Arabia
and the year of diagnosis for each case. This study
was conducted using these reports from the SaudiHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comCancer Registry with the aim of presenting the
descriptive epidemiology of prostate cancer in Saudi
Arabia.
For data analysis, we used the Statistical Package
for the Social Sciences version 20.0 (SPSS). The
descriptive analysis of the epidemiological data was
performed by calculating the overall percentage, the
CIR and the ASIR adjusted by the age group, region
and year of diagnosis. The percentage was calculated
by adding the number of prostate cancer cases and
then dividing that number by the total number of
male cancer cases. Furthermore, analysis of variance
test (ANOVA) was performed to determine any sig-
niﬁcant differences among the regions and years of
diagnosis.11 In addition, the linear regression model
that investigates the strength of the association be-
tween independent variables and an outcome was ap-
plied to predict the annual CIR and the ASIR for
prostate cancer among Saudi men.12 In addition, the
Poisson regression model was conducted to calculate
the incidence rate ratio of prostate cancer cases in
each region of Saudi Arabia.19
Figure 1. (A and B) Num
distribution by age group
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The overall age-standardised rates per 100,000
men were calculated for all of Saudi cancer registry re-
ports based on the world standard of Segi (1960) for
populations who have an intermediate-age population
(Table 1). This is a particularly important rate when
making comparisons between different populations
with respect to the age structure.13,14RESULTS
A total of 1739 cases were recorded in the SCR be-
tween January 2001 and December 2008. The fre-
quency of prostate cancer cases increased slightly
from 2001 to 2008. Figure 1a and b show 156 cases
(5.4%, 95% CI, 3.5% to 7.3%). This ﬁgure rose to
176 cases in 2002, representing an increase of 0.5%.
In 2005, 261 cases were reported, corresponding to
a 1.6% increase. This was the highest ﬁgure reported
by the SCR (2005). However, the ﬁgure dropped
from 2005 to 2008 by 0.7%.ber and percentage of prostate cancer cases in Saudi Arabia from 2001 to
in Saudi Arabia from 2001 to 2008.
HeThe average number and percentage of prostate
cancer cases between 2001 and 2008 adjusted by
age group, was calculated from the SCR (Table 2)
and (Figure 1c and d). The age groups reported cor-
respond to 00–44, 45–59, 60–74, and over 75 years.
According to the overall numbers and percentages, the
age groups that recorded the highest affected by pros-
tate cancer were men aged 60–74 years, with 111
cases, representing 50.7% of the total number of pros-
tate cancer cases, followed by those over 75 years,
with 80 cases, representing 37.5%. The younger group
aged 00–44 years recorded the lowest overall number
and percentage with two cases, representing less than
1% of the total number of prostate cancer cases, fol-
lowed by men aged 45–59 years with 24 cases, repre-
senting 10.8%.
The CIRs adjusted by year of diagnosis from 2001
to 2008 per 100,000 men indicate a steady increase of
prostate cancer among men in Saudi Arabia.
According to Table 3 and Figure 2a, a CIR of 1.92008. (C and D) Overall number and percentage of prostate cancer case
matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 2. Prostate cancer cases distribution by age group in Saudi Arabia from 2001 to 2008.
Age Group
0–44 45–59 60–74 75 Total Median age Range of age
Year No % No % No % No % Total % Year Minimum year Maximum year
2001 1 0.6 12 7.4 65 42.0 78 50 156 5.4 72 44 94
2002 1 0.5 17 10.0 92 52.0 66 37.5 176 5.9 72 43 98
2003 4 2.2 16 9.0 95 53.4 63 35.4 178 5.5 72 44 98
2004 2 1.0 26 12.0 109 51.0 77 36.0 214 6.2 71 25 107
2005 2 1.0 23 9.0 149 57.0 87 33.0 261 7.0 71 6 103
2006 2 1.0 30 13.0 103 45.0 93 41.0 228 5.8 71 1 101
2007 3 1.0 40 15.0 137 53.0 79 31.0 259 6.0 70 10 100
2008 3 1.0 30 11.0 138 52.0 96 36.0 267 6.3 70 41 107
Average 2 1.0 24 11.0 111 51.0 80 38.0 217 6.0 71 27 101
There are no significant differences between years of diagnosis p-value > 0.05.
Table 3. Confidence Interval for%, CIR and ASIR of prostate cancer cases in Saudi Arabia from 2001 to 2008.
Percentage CIR per 100,000 ASIR per 100,000
Year % 95% CI Lower 95% CI Upper CIR 95% CI Lower 95% CI Upper ASIR 95% CI Lower 95% CI Upper
2001 5.4 3.5 7.3 1.9 1.4 2.4 3.4 2.1 4.8
2002 5.9 4.4 7.4 2.3 1.6 3.0 4.0 2.1 5.9
2003 5.5 3.6 7.4 2.2 1.6 2.9 4.2 2.4 6.0
2004 6.2 4.5 7.9 2.6 1.9 3.3 5.1 3.6 6.7
2005 7.0 5.3 8.7 3.1 2.3 3.9 6.2 4.5 7.9
2006 5.8 4.6 7.0 2.6 1.9 3.3 6.1 4.6 7.6
2007 6.0 3.9 8.1 2.9 2.0 3.8 5.7 3.5 7.9
2008 6.3 4.3 8.4 2.9 2.1 3.7 5.7 4.0 7.4
Overall 6.0 4.2 7.8 2.6 1.9 3.3 5.1 3.3 6.8
RATE OF PROSTATE CANCER IN SAUDI ARABIA original research report(95% CI, 1.4 to 2.4) per 100,000 men was estimated
in 2001, and a CIR of 2.9 (95% CI, 2.1 to 3.7) per
100,000 men was estimated in 2008. In 2005, the
CIR of 3.1 (95% CI, 2.3 to 3.9) per 100,000 men
was the highest rate, but was not statistically signiﬁ-
cant compared to the other years: F(7, 96) = 0.76,
p > 0.05. However, this ﬁgure dropped by 0.2% in
2008. Based on the linear regression model, the
equation for a straight line to predict the annual
CIR of prostate cancer in Saudi Arabia isHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com1.53 + (0.094 · Years), and the incidence rate of
prostate cancer increased by a predicted average of
0.094 per 100,000 Saudi men per year.
The overall CIR of prostate cancer adjusted by the
regions of Saudi Arabia from 2001 to 2008 per
100,000 men was calculated from the SCR, as shown
in Table 4 and Figure 2b The eastern region of Saudi
Arabia had the highest overall CIR for prostate cancer
at 3.5 (95% CI, 3.1 to 3.9) per 100,000 men, followed
by Riyadh at 3.0 (95% CI, 2.6 to 3.5) and Makkah at21
Figure 2. (A) The crude incidence rate of prostate cancer cases in Saudi Arabia from 2001 to 2008. (B) Overall crude incidence rate of prostate cancer cases distribution by
region in Saudi Arabia from 2001 to 2008. (C) The age-standardised incidence rate of prostate cancer cases in Saudi Arabia from 2001 to 2008. (D) Overall age-standardised
incidence rate of prostate cancer case distribution by region in Saudi Arabia from 2001 to 2008.
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variance test revealed that the incidence rates of pros-
tate cancer were signiﬁcantly higher for these regions
compared to other parts of Saudi Arabia: F(12,
91) = 8.483, p < 0.001. Furthermore, Jizan (95%
CI, 0.8 to 1.4), and Najran (95% CI, 0.4 to 1.9)
had the lowest average CIRs for prostate cancer
among Saudi men at 1.1 and 1.2, respectively. How-
ever, the ﬁgures for these regions were generally in
agreement with increasing or decreasing ASIR.
The world age-standardised incidence rate of pros-
tate cancer per 100,000 men, adjusted for the region
and the year of diagnosis, suggests a similar trend to
that seen for the CIR from 2001 to 2008 (Figure 2c
and d). There was a slight increase in the cases of
prostate cancer diagnosed between 2001 and 2008,
with the highest ASIR of 6.2 reported in 2005
(95% CI, 4.5 to 7.9), followed by a slight decrease
in the ASIR to 5.7 in 2008 (95% CI, 4.0 to 7.4),Heaccording to reports released by the SCR. However,
the equation for the straight line to predict the annual
ASIR of prostate cancer in Saudi Arabia is
2.97 + (0.182 · Years), and the ASIR of prostate
cancer increased by a predicted average of 0.182 per
100,000 Saudi men per year. Similarly, the eastern
part of Saudi Arabia had the highest mean ASIR at
10.1 (95% CI, 8.6 to 11.6), followed by Riyadh at
7.1 (95% CI, 5.7 to 8.5) and Makkah at 5.2 (95%
CI, 3.9 to 6.6). Therefore, the analysis of variance
was statistically signiﬁcant for these regions compared
to other provinces of Saudi Arabia: F(12,
91) = 18.693, p < 0.001. Jizan (95% CI, 0.7 to 2.2)
and Najran (95% CI, 0.7 to 3.2) had the lowest mean
ASIRs at 1.4 and 2.0, respectively.
The Poisson regression model was conducted to
calculate the incidence rate ratio (IRR) of prostate
cancer cases in different regions of Saudi Arabia.
The model was statistically signiﬁcant: LR v2matol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 4. Confidence Interval for overall%, CIR and ASIR of prostate cancer cases in the regions of Saudi Arabia from 2001 to 2008.
Regions Overall percentage Overall CIR Overall ASIR
% 95% CI Lower 95% CI Upper CIR 95% CI Lower 95% CI Upper ASIR 95% CI Lower 95% CI Upper
Asir 7.0 5.0 9.1 2.6 1.8 3.4 3.7 2.5 4.9
Baha 8.3 4.8 11.8 2.8 1.5 4.0 2.9 1.5 4.3
Jizan 4.8 3.3 6.2 1.1 0.8 1.4 1.4 0.7 2.2
Madinah 4.5 3.0 6.0 1.6 1.0 2.2 3.0 2.2 3.7
Hail 4.6 1.4 7.8 1.4 0.5 2.3 2.1 0.4 3.7
Qassim 4.3 3.0 5.5 1.6 1.2 2.0 2.6 1.8 3.4
Riyadh 6.0 5.3 6.7 3.0 2.6 3.5 7.1 5.7 8.5
Makkah 6.1 5.0 7.2 2.9 2.2 3.7 5.2 3.9 6.6
Najran 3.9 1.1 6.6 1.2 0.4 1.9 2.0 0.7 3.2
Jouf 5.7 2.9 8.5 1.8 1.0 2.6 4.2 2.2 6.2
Tabuk 2.8 1.7 3.9 1.0 0.6 1.4 3.0 1.6 4.4
Eastern Region 7.7 6.9 8.5 3.5 3.1 3.9 10.1 8.6 11.6
Northern Region 5.5 3.6 7.3 2.0 1.4 2.7 3.9 2.6 5.2
Table 5. Poisson regression model to calculate the IRR and check if there is an effect due to geographical area, year of diagnosis, CIR and ASIR.
No cases Incidence rate ratio P-value 95% CI
Regions
1. Asir 0.31 0.14 (0.22–0.40)
2. Baha 0.25 0.12 (0.15–0.35)
3. Jizan 1 Reference 1
4. Madinah 0.56 0.20 (0.44–0.68)
5. Hail 0.19 0.08 (0.11–0.27)
6. Qassim 0.38 0.15 (0.26–0.51)
7. Riyadh 3.43 0.001* (3.13–3.73)
8. Makkah 2.56 0.001* (2.38–2.74)
9. Najran 0.11 0.001* (0.06–0.17)
10. Jouf 0.16 0.06 (0.11–0.22)
11. Tabuk 0.20 0.09 (0.14–0.26)
12. Eastern Region 1.93 0.001* (1.64–2.23)
13. Northern Region 0.06 0.001* (0.02–0.11)
Years 1.0 0.002* (0.99–1.04)
CIR 1.5 0.001* (1.40–1.66)
ASIR 0.98 0.39 (0.96–1.11)
(*) means the significance level is <0.05. When the P-value is less than 0.05, the result is statistically significant.
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Table 6. The differences in the percentage, CIR and ASIR of prostate cancer cases in the regions of Saudi Arabia between 2001 and 2008.
Regions Percentage% CIR per 100,000 ASIR per 100,000
2008 2001 difference P-value 2008 2001 difference P-value 2008 2001 difference P-value
Asir 6.9 7.5 .60 0.88 2.6 2.1 .5 0.81 3.6 2.9 .7 0.87
Baha 16.1 7.7 8.4 0.02* 5.6 1.4 4.2 0.03* 6.3 2.2 4.1 0.04*
Jizan 3.1 4.8 1.7 0.54 0.8 1.2 .4 0.77 1.1 0.7 .4 0.77
Madinah 5.2 7.5 2.3 0.52 2.4 2.0 .4 0.84 4.1 3.3 .8 0.77
Hail 4.3 11.7 7.4 0.06 1.7 3.1 1.4 0.52 1.9 6 4.1 0.14
Qassim 4.1 2.3 1.8 0.48 1.5 1.4 .1 0.96 2.6 2.3 .3 0.89
Riyadh 7.0 4.9 2.1 0.54 3.9 2.6 1.3 0.61 9.4 5.4 4.0 0.29
Makkah 5.7 3.7 2.0 0.51 2.8 1.3 1.5 0.45 5.0 2.2 2.8 0.29
Najran 3.4 3.6 .20 0.94 1.0 1.2 .2 0.89 2.2 1.6 .6 0.67
Jouf 4.5 5.6 1.1 0.73 1.8 1.3 .5 0.77 4.6 2.8 1.8 0.51
Tabuk 3.9 2.8 1.1 0.67 1.5 1.0 .5 0.75 4.9 3.0 1.9 0.51
Eastern Region 7.4 7.6 .20 0.96 3.7 3.0 .7 0.78 10.5 8.2 2.3 0.59
Northern Region 8.0 10.0 2.0 0.63 3.1 0.7 2.4 0.21 5.7 3.9 1.8 0.56
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was the reference region for making comparisons be-
tween other provinces of Saudi Arabia; the IRRs were
signiﬁcantly higher (p < 0.001), for the regions of
Riyadh at 3.43 times (95% CI, 3.13–3.73), followed
by Makkah at 2.56 (95% CI, 2.38–2.74) and the east-
ern region at 1.93 (95% CI, 1.64–2.23). Furthermore,
the percentage change in the IRR of prostate cancer
cases was signiﬁcantly higher with an increase of 1%
for every unit increase in one year and 1.5% for every
unit increase in CIR.
The differences in the CIR and the ASIR between
2001 and 2008 were calculated from the data in the
SCR to investigate the pattern of prostate cancer
among older Saudi men in different regions (Table 6).
The greatest changes in percentages were observed
only in the region of Baha (16.1%, 4.2 CIR, 4.1
ASIR). However, the CIR and ASIR for all regions,
with the exception of Baha, are still under the pre-
dicted values based on the equations for the linear
regression: 1.53 + (0.094 · 8 Years = 2.28) per
100,000 men for the CIR and
2.97 + (0.184 · 8 Years = 4.44) per 100,000 men
for the ASIR. The smallest changes in CIR and ASIR
were detected in the regions of Hail (7.4%, 1.4
CIR, 4.1 ASIR), and Jizan (1.7%, 0.4 CIR,
0.4 ASIR). Therefore, these regions recorded down-
trending rates from 2001 to 2008.HeDISCUSSION
This is the ﬁrst epidemiological study of prostate can-
cer in Saudi Arabia. It describes the pattern of the
disease during the years 2001–2008. This study pro-
vides an important explanation for the recent trend,
supporting the signiﬁcance of the disease. Our results
conﬁrm that the eastern region, Riyadh and Makkah
have the highest overall CIRs and ASIRs for prostate
cancer among men in Saudi Arabia. In addition, the
overall CIRs and ASIRs in these regions increased
above the expected levels of 2.25 per 100,000 men
for the CIR and 4.44 per 100,000 men for the ASIR
during the years 2001 to 2008.
Our results also conﬁrm that the regions of Jizan
and Najran have the lowest values in the average
CIR and ASIR. The age group most affected by pros-
tate cancer in Saudi Arabia and in other developed
countries is of men above 65 years of age.15,16 Despite
the extensive use of prostate speciﬁc antigen (PSA)
screening for early detection of the presence of the
disease in both younger and older men, incidence
rates in men older than 65 years remain high.16 How-
ever, in some clinical trial studies, PSA has proved to
be a major limitation for identifying the true cases of
prostate cancer, with false positive results recorded
due to lack of sensitivity of the test.17,18 Other studies
have speciﬁed that the PSA screening test decreasedmatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
Table 7. The ASIR and ASMR of prostate cancer across different countries of the world.
Estimated by the International Agency for Research on Cancer (IARC) 2008.
Country Age standardised incidence rate ASIR per
100,000 men
Age standardised mortality rate
ASMR per 100,000 men
Ireland 126.3 13
Australia 105 15.4
USA 83.8 9.7
UK 64 13.8
Lebanon 25.4 17.7
Qatar 15 8.4
Jordan 13.9 10.2
Bahrain 13.3 5.9
Kuwait 11.6 5
UAE 9.6 4.5
Oman 9 5.6
Saudi
Arabia
7.7 5.1
Egypt 6.6 5.1
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the mortality rate of prostate cancer by 20%, but was
associated with over-diagnosis.19,20
In this study, we have reported the changes in the
percentage, the CIR and the ASIR from 2001 to
2008. Baha had the highest differences in rates, which
were above the predicted value of 2.25 per 100,000
men for the CIR during the years 2001–2008. In addi-
tion, it had the highest difference in the ASIR, and was
very close to the predicted value of 4.44 per 100,000
Saudi men. These differences suggest that the region
of Baha was signiﬁcantly affected by prostate cancer
over the eight-year period (2001–2008). However,
the rates of prostate cancer decreased in the regions of
Hail and Jizan over the same period. These regions
had the lowest changes with down-trending in the
CIR and ASIR from 2001 to 2008.
In 2008, the ASIRs and ASMRs of prostate can-
cer were reported in Saudi Arabia at 7.7 per 100,000
men. These were considered very low in comparison
to both Arab Gulf countries and other world coun-
tries (Table 7). Ireland had the highest ASIR of pros-
tate cancer in the world at 126.3 per 100,000 men.
This ﬁgure was 16-fold higher than Saudi Arabia.
However, the pattern and trend of prostate cancer
should be monitored and not neglected due to low
ASIR and ASMR.7
It is important to note that these results are useful
to health researchers in Saudi Arabia for generating
hypotheses about the potential risk factors of prostate
cancer in the highest affected regions, and for con-
ducting analytic epidemiologic studies that identify
the relationships between exposure and disease.13
However, the availability of data from SCR reports
encourages further descriptive epidemiological studies
of other types of cancers among the Saudi population.CONCLUSION
It is clear from the epidemiological analysis of the re-
ports registered by the Saudi Cancer Registry from
2001 to 2008 that the CIR and ASIR of prostate can-
cer are steadily increasing. The regions of Jizan andHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comNajran had the lowest average CIRs and ASIRs,
while the Poisson regression model and linear trend
are a concern in certain regions, such as the eastern
region, Riyadh and Makkah. As mentioned earlier,
the region of Baha recorded the greatest differences
of the CIR and ASIR between 2001 and 2008, while
the regions of Hail and Jizan recorded the lowest.
However, further effective screening programs are
needed across Saudi Arabia, and active treatment
measures should be implemented to control prostate
cancer among Saudi men.CONFLICT OF INTEREST
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